Cancer Clinical Trials

Find a clinical trial, talk with your doctor to learn if you are eligible.

Updated June 2022

Cancer Type Trial Name Site
NRG-BR004: A Randomized, Double-Blind, Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer. Norwalk/Danbury
OTS1070103: A Phase I Study of OTS167PO,a MELK inhibitor, to Evaluate Safety, Tolerability and Pharmacokinetics in Patients with Advanced Breast Cancer and Dose-Expansion Study in Patients with Triple Negative Breast cancer Norwalk
SGNLVA-001: A phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with metastatic breast cancer Norwalk
SGNLVA-002: Single Arm, Open Label Phase 1b/2 Study of SGN-LIV1A in Combination with Pembrolizumab for First-Line Treatment of Patients with Unresectable Locally-Advanced or Metastatic Triple-Negative Breast Cancer Norwalk
A011202: A Randomized, Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3N1) Who Have Positive Sentinel Lymph Node Disease after Neoadjuvant Chemotherapy
ARV-471-mBC-101: A Phase 1/2, open label, dose escalation, and cohort expansion clinical trial to evaluate the safety, tolerability, and pharmacokinetics of ARV-471 alone and in combination with palbociclib (IBRANCE®) in patients with estrogen receptor positive/human epidermal growth factor receptor 2 negative (ER+/HER2-) locally advanced or metastatic breast cancer, who have received prior hormonal therapy and chemotherapy in the locally advanced/metastatic setting Norwalk
18-002: A Phase I Study of Rucaparib Administered Concurrently with Postoperative Radiotherapy in Patients with Triple Negative Breast Cancer with an Incomplete Pathologic Response Following Neoadjuvant Chemotherapy Norwalk
18-109: A Feasibility Study of Flibanserin in Breast Cancer Survivors on Tamoxifen or Aromotase Inhibitors Norwalk
19-401: Triple Negative Breast Cancer Clinic Program at Norwalk Hospital Norwalk
A011801: The COMPASSHER2 Trials ( COMprehensive  Use of Pathologic Response Assessment to Optimize Therapy in HER2-Positive Breast Cancer): CompassHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and Tucatnib.
A191901:Optimizing Endocrine Therapy Through Motivational Interviewing and Text Interventions
Breast & Lung 18-486  PROMISE-005: A Phase II Randomized Study Assessing the Efficacy of Stereotactic Body Radiotherapy (SBRT) in Patients with Oligometastatic Breast or Lung Cancer Norwalk
Lung A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial
E4512: A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib Versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Thoracic Surgery IELCART: Initiative for Early Lung Cancer Research on Treatment
PLOTS: Intraoperative, Percutaneous Localization of Peripheral Pulmonary Nodules for Resection: A Prospective, Open-Label, Multi-Center Registry Study of Thoracic Surgery Outcomes
NRG-GY018: A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475) in addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer
NRG-GY020: “Randomized Phase III Trial of Radiation +/- MK-3475 (Pembrolizumab) for Newly Diagnosed Early Stage High Intermediate Risk Mismatch Repair Deficient (DMMR) Endometrioid Endometrial Cancer.
NRG-CC008: A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers [SOROCk] Danbury/Norwalk 
NRG-GY023: A Randomized Phase II Trial of Triplet Therapy (a PD-L1 Inhibitor Durvalumab (MEDI4736) in Combination with Olaparib and Cediranib) Compared to Olaparib and Cediranib or Durvalumab (MEDI4736) and Cediranib or Standard of Care Chemotherapy in Women with Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Cancer Who Have Received Prior Bevacizumab Danbury/Norwalk
Pancreas 15-10: The Role of MicroRNAs in the Diagnosis, Prognosis and Response to Treatment in Pancreatic Cancer
Norwalk/Danbury/New Milford
16-15: Pre- and Post-Surgical Molecular Testing in Individuals with Operable Pancreatic Cancer
Norwalk/Danbury/New Milford
16-17: A Pancreatic Cancer Screening Study in High Risk Individuals
Norwalk/Danbury/New Milford
18-01: A Pancreatic Cancer Screening Study in High Risk Individuals Including those with Recent-Onset Diabetes Mellitus
Norwalk/Danbury/New Milford
A021806: A phase III trial of perioperative versus adjuvant chemotherapy for resectable pancreatic cancer
TD2-PDAC-KETO-001: Randomized Phase II Trial of Two Different Nutritional Approaches for Patients Receiving Treatment for Their Advanced Pancreatic Cancer
S2001: Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab vs. Olaparib Alone as Maintenance Therapy in Metastatic Pancreatic Cancer Patients with Germline BRCA1 or BRCA2 Mutations Norwalk/Danbury 
15-35: Serum-based Signature of Activation of the PD-1/PD-L1 Pathway in Patients with Cancer. Serial serum samples from patients starting immune-based therapies that target the PD-1/PDL-1 pathway in cancer patients.
Norwalk/Danbury/New Milford
BB001: The Western Connecticut Health Network (WCHN), Danbury and Norwalk Hospitals Biobank - A Collection of Biospecimens and Clinical Data to Facilitate Research (GYN Biobank)
Norwalk/Danbury/New Milford
S2013: “Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study” Norwalk/Danbury 
2200003: A Prospective Study to Achieve Health Equity in Biomarker Analysis for Underrepresented Communities Receiving Cancer Treatment at Nuvance Health
Basket Trial
C2321001: A Phase I dose escalation and expanded cohort study of PF-06821497 in the treatment of adult patients with Relapsed/refractory Small Cell Lung Cancer (SCLC), Castration Resistant Prostate Cancer (CRPC) and follicular lymphoma Norwalk
AMG 510 20190135: A Phase 1b, Master Protocol Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 510 in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation
ONC-392-001: Safety, Pharmacokinetics (PK), and Efficacy of ONC-392 as a Single Agent and in Combination with Pembrolizumab in Advanced Solid Tumors and NSCLC: An Open Label Phase IA/IB Study.